Alizyme to start Phase IIb

Alizyme (LSE:AZM) will begin a 500-patient Phase IIb trial of its ATL-1251 renzapride in constipation-predominant irritable bowel syndrome (IBS). The double-blind, placebo-controlled trial will enroll...